Michael Barbella, Managing Editor04.02.24
Eko Health has received U.S. Food and Drug Administration (FDA) clearance for its Low EF detection AI. The tool enables U.S. physicians for the first time to detect Low EF—a key heart failure indicator—in 15 seconds using an Eko stethoscope during a routine physical examination.
More than 6 million people in the United States suffer from heart failure, with half of them experiencing heart failure with reduced ejection fraction (HFrEF)—a condition marked by the heart's inability to pump blood effectively.1 Traditional heart failure detection tools, such as echocardiography, are often unavailable in primary care settings because they are costly, require specialized training, and add significant time. Consequently, many heart failure cases go undiagnosed until symptoms force a specialist or emergency hospital visit, leading to worse patient outcomes and exacerbated healthcare costs.2 Eko's Low EF AI embeds rapid and accessible low ejection fraction detection into a stethoscope exam.
“The ability to identify a hidden, potentially life-threatening heart condition using a tool that primary care and subspecialist clinicians are familiar with—the stethoscope—can help us prevent hospitalizations and adverse events,” said Dr. Paul Friedman, chair of the Department of Cardiovascular Medicine at Mayo Clinic. “Importantly, since a stethoscope is small and portable, this technology can be used in urban and remote locations, and hopefully help address care in underserved areas.”
The Low EF AI will be added to Eko’s SENSORA Cardiac Early Detection Platform, the latest advancement to the platform which already features FDA-cleared algorithms to identify AFib and structural heart murmurs, often an indicator of valvular heart disease. When Low EF is detected in a primary care exam with SENSORA, access to life-extending treatment can be expedited with a referral to the cardiology department for thorough diagnostic testing and treatment evaluation.
“The stethoscope, the most recognizable symbol of healthcare, touches the lives of an estimated one billion people around the globe every year,” Eko Health Co-Founder/CEO Connor Landgraf stated. “With Eko’s Low EF AI, we’ve transformed the icon of medicine into an AI-powered heart failure early detection tool that can help improve access to care for millions of patients, at a fraction of the time and cost of echocardiography. It’s been a privilege to work alongside the Mayo Clinic in this endeavor.”
Clinical development and validation highlights:
Mayo Clinic and Friedman have a financial interest in Eko Health's technology. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
References
1 Centers for Disease Control and Prevention. (2023, January 5). Heart failure. https://www.cdc.gov/heartdisease/heart_failure.htm
2 Bachtiger P, Kelshiker MA, Petri CF, et al. (2023). Survival and health economic outcomes in heart failure diagnosed at hospital admission versus community settings: a propensity-matched analysis. BMJ Health & Care Informatics, 30:e100718. doi: 10.1136/bmjhci-2022-100718
3 FDA 510(k) Summary, K233409
4 Bachtiger, P., et al. (2022). Point-of-care screening for heart failure with reduced ejection fraction using artificial intelligence during ECG-enabled Stethoscope Examination in London, UK: A prospective, observational, multicentre study. The Lancet Digital Health, 4(2).
5 Adedinsewo DA. (2023, November 13). Screening for peripartum cardiomyopathies using an artificial intelligence enhanced digital stethoscope: a randomized clinical trial [Conference Presentation and Abstract]. AHA 2023, Philadelphia, PA, United States.
More than 6 million people in the United States suffer from heart failure, with half of them experiencing heart failure with reduced ejection fraction (HFrEF)—a condition marked by the heart's inability to pump blood effectively.1 Traditional heart failure detection tools, such as echocardiography, are often unavailable in primary care settings because they are costly, require specialized training, and add significant time. Consequently, many heart failure cases go undiagnosed until symptoms force a specialist or emergency hospital visit, leading to worse patient outcomes and exacerbated healthcare costs.2 Eko's Low EF AI embeds rapid and accessible low ejection fraction detection into a stethoscope exam.
“The ability to identify a hidden, potentially life-threatening heart condition using a tool that primary care and subspecialist clinicians are familiar with—the stethoscope—can help us prevent hospitalizations and adverse events,” said Dr. Paul Friedman, chair of the Department of Cardiovascular Medicine at Mayo Clinic. “Importantly, since a stethoscope is small and portable, this technology can be used in urban and remote locations, and hopefully help address care in underserved areas.”
The Low EF AI will be added to Eko’s SENSORA Cardiac Early Detection Platform, the latest advancement to the platform which already features FDA-cleared algorithms to identify AFib and structural heart murmurs, often an indicator of valvular heart disease. When Low EF is detected in a primary care exam with SENSORA, access to life-extending treatment can be expedited with a referral to the cardiology department for thorough diagnostic testing and treatment evaluation.
“The stethoscope, the most recognizable symbol of healthcare, touches the lives of an estimated one billion people around the globe every year,” Eko Health Co-Founder/CEO Connor Landgraf stated. “With Eko’s Low EF AI, we’ve transformed the icon of medicine into an AI-powered heart failure early detection tool that can help improve access to care for millions of patients, at a fraction of the time and cost of echocardiography. It’s been a privilege to work alongside the Mayo Clinic in this endeavor.”
Clinical development and validation highlights:
- AI training and validation: Eko’s Low EF AI was trained on a proprietary dataset of more than 100,000 ECGs and echocardiogram pairs from unique patients, and was clinically validated in a multi-site, prospective clinical study of 3,456 patients, achieving a 0.835 AUROC for detecting LVEF <40%, 74.7% sensitivity and 77.5% specificity, demonstrating a strong ability to differentiate between low and normal EF.3
- Imperial College London independent validation: An independent validation of the Low EF AI by the Imperial College London, published in Lancet Digital Health, reported a 0.85 AUROC for detecting LVEF below 40%, 84.8% sensitivity, and 69.5% specificity when deployed on more than 1,050 patients across multiple real-world settings. This validation prompted the UK NHS and Imperial College London to extend Eko's deployment to more than 100 clinics in London and Wales.4
- Demonstrated impact in pregnant women: A clinical study led by the Mayo Clinic involving nearly 1,200 pregnant women in Nigeria highlighted the AI's effectiveness, identifying twice as many cases of pregnancy-related cardiomyopathy than standard care, with a 0.98 AUROC, 100.0% sensitivity, and 79.4% specificity, underscoring its significant potential to assist in the detection and appropriate management of cardiomyopathy in pregnant women, reducing associated disease burden and risk of death.5
Mayo Clinic and Friedman have a financial interest in Eko Health's technology. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
References
1 Centers for Disease Control and Prevention. (2023, January 5). Heart failure. https://www.cdc.gov/heartdisease/heart_failure.htm
2 Bachtiger P, Kelshiker MA, Petri CF, et al. (2023). Survival and health economic outcomes in heart failure diagnosed at hospital admission versus community settings: a propensity-matched analysis. BMJ Health & Care Informatics, 30:e100718. doi: 10.1136/bmjhci-2022-100718
3 FDA 510(k) Summary, K233409
4 Bachtiger, P., et al. (2022). Point-of-care screening for heart failure with reduced ejection fraction using artificial intelligence during ECG-enabled Stethoscope Examination in London, UK: A prospective, observational, multicentre study. The Lancet Digital Health, 4(2).
5 Adedinsewo DA. (2023, November 13). Screening for peripartum cardiomyopathies using an artificial intelligence enhanced digital stethoscope: a randomized clinical trial [Conference Presentation and Abstract]. AHA 2023, Philadelphia, PA, United States.